Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review
Authors:
- Valentina BaroVBValentina Baro
- Giulia CerrettiGCGiulia Cerretti
- Michela TodovertoMTMichela Todoverto
- Alessandro Della PuppaAPAlessandro Della Puppa
- Franco ChioffiFCFranco Chioffi
- Francesco VolpinFVFrancesco Volpin
- Francesco CausinFCFrancesco Causin
- Fabio BusatoFBFabio Busato
- Pasquale FiducciaPFPasquale Fiduccia
- Andrea LandiAndrea Landi
- Domenico D’avellaDDDomenico D’avella
- Vittorina ZagonelVZVittorina Zagonel
Open Access
- 11 May 2022
- journal article
- review article
- Published by MDPI AG in Current Oncology
- Vol. 29 (5) , 3472-3488
Abstract
Glioblastomas with multiple foci at presentation (mGBMs) account for 2–35% of all GBMs. mGBMs have limited existing data and no standardized treatment. This study aims to determine their incidence, demographic and clinical features, outcome, and prognostic factors in terms of overall survival. We performed a monocentric retrospective study, reviewing patients treated at the Istituto Oncologico Veneto. Inclusion criteria were: new diagnosis of GBM and presence of multiple lesions on pre-treatment MRI. ECOG PS was used to evaluate clinical condition, RANO criteria for radiological assessment, and CTCAE v5.0 for treatment-related adverse events. The incidence of newly diagnosed mGBM was 7.2% and the study population consisted of 98 patients. Median age was 63 years, M:F ratio of 1.8:1, and a surgical approach was undertaken in 73 patients (mostly partial resection). MGMT was methylated in 47.5%, and 82 patients received active oncological treatment (65.9% radiotherapy plus temozolomide (RT + TMZ)). The disease control rate with RT + TMZ was 63%. Median OS of the entire study population was 10.2 months (95% CI 6.6–13.8), and median PFS was 4.2 months (95% CI 3.2–5.2). The ECOG PS, the extent of resection, and the RT + TMZ were significant prognostic factors in the univariate analysis for OS, but only the RT + TMZ was a significant independent OS predictor in the multivariate analysis (HR = 3.1, 95% IC 1.3–7.7, p = 0.014). The incidence of mGBM is not rare. RT + TMZ is confirmed to be an independent prognostic factor for survival and a safe and effective treatment. When feasible, RT + TMZ should be considered as a possible first-line treatment. The role of the extent of resection is still unclear.Keywords
This publication has 32 references indexed in Scilit:
- Multiple craniotomies in the management of multifocal and multicentric glioblastomaJournal of Neurosurgery, 2011
- Diagnosis and Management of Multifocal GliomasOncology, 2010
- MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastomaNeuro-Oncology, 2009
- POSITRON EMISSION TOMOGRAPHY-GUIDED VOLUMETRIC RESECTION OF SUPRATENTORIAL HIGH-GRADE GLIOMASNeurosurgery, 2009
- Multifocal Glioblastoma Multiforme: Prognostic Factors and Patterns of ProgressionInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes ProjectJournal of Neurosurgery, 2003
- Imaging patterns of multifocal gliomasEuropean Journal of Radiology, 1993
- The Problem of Multicentric GliomasJournal of Neurosurgery, 1963